Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients

BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from the α-galactosidase A gene mutations. Enzyme-replacement-therapy (ERT) products for FD currently used include agalsidase alfa and agalsidase beta. There are many reports on efficacy and safety of ERT. However, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuboi, Kazuya, Yamamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463328/
https://www.ncbi.nlm.nih.gov/pubmed/28592315
http://dx.doi.org/10.1186/s40360-017-0152-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463328/
https://www.ncbi.nlm.nih.gov/pubmed/28592315
http://dx.doi.org/10.1186/s40360-017-0152-7

Ejemplares similares